Citations

Showing 10 of 108119 citations.

Tourniquet Use in Total Knee Arthroplasty
Arthur, Jaymeson R. , Spangehl, Mark J.

Mayo Clinic

The Journal of Knee Surgery | March 2, 2019 | Volume: 32 | Issue: 08 | Pages: 719-729

10.1055/s-0039-1681035 | PMID 30822788 Get It

AbstractTourniquet use in total knee arthroplasty has become a controversial topic. There are several benefits of its use including improved visualization, decreased blood loss, shorter operative times, and improved antibiotic delivery. Conversely, there are several significant downsides associated with tourniquet use including postoperative pain, neuromuscular injuries, wound complications, reperfusion injury, increased risk of thrombosis, patellar tracking issues, delayed rehabilitation including decreased postoperative range of motion, and its negative effect on patients with vascular disease. However, objectively, the literature does not definitively push us toward or away from the use of a tourniquet. Furthermore, several alternatives have been developed to help mitigate some of the adverse effects associated with its use. This article summarizes the evidence for and against tourniquet use and provides an evidence-based approach to help guide surgeons in their own practice.
Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2
Zhou, Bo , Ho, Steve S. , Greer, Stephanie , Spies, Noah , Bell, John , Zhang, Xianglong , Zhu, Xiaowei , Arthur, Joseph G. , Byeon, Seunggyu , Pattni, Reenal , Saha, Ishan , Huang, Yi‐Ling , Song, Giltae , Wong, Wing Hung , Ji, Hanlee P. , Abyzov, Alexej , Urban, Alexander E. , Zhou, Bo , Abyzov, Alexej , Perrin, Dimitri

Mayo Clinic

Nucleic Acids Research | March 1, 2019 | Volume: 47 | Issue: 8 | Pages: 3846-3861

10.1093/nar/gkz169 | PMID 30864654 Get It

Home Blenderized Tube Feeding: A Practical Guide for Clinical Practice
Weeks, C. R. , Weeks, Caroline

Mayo Clinic

Clinical and Translational Gastroenterology | March 1, 2019 | Volume: 10 | Issue: 2 | Pages: e00001

10.14309/ctg.0000000000000001 | PMID 30730397 Get It

Although commercial enteral formulas have been available on the market for several decades, a cultural shift toward consuming unprocessed foods with minimally added sugar has sparked interest in the preparation of home blenderized tube feedings for enteral feeding-dependent patients. Recent surveys, however, indicate lack of clinical awareness or familiarity in the management of this method of nutrition support. This article aims to equip the gastroenterologist with a guide for initiation, monitoring, and evaluation of a blenderized tube feedings regimen, and provides insights into an opportunity for greater partnership between the gastrointestinal provider and registered dietitian.
Translabyrinthine Approach for Resection of Vestibular Schwannoma
Feng, Yening , Patel, Neil , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 1, 2019 | Volume: 80 | Issue: S 03 | Pages: S286-S286

10.1055/s-0039-1677856 | PMID 31143593 Get It

Objectives This video describes the surgical indications, relevant anatomy, and surgical steps of routine translabyrinthine surgery for gross total resection of sporadic vestibular schwannoma. Design The procedure is presented through a surgical instructional video. Setting The surgery took place at tertiary skull base referral center. Parcipant A 47-year-old patient reported with nonserviceable hearing, frequent episodes of vertigo, recurrent severe headache, and a small unilateral right sided vestibular schwannoma. Results Gross total resection with preservation of facial nerve function was achieved. Conclusion This instructional video documents the surgical steps and relevant anatomy for translabyrinthine resection of vestibular schwannoma.The link to the video can be found at: https://youtu.be/CJ2vKMLs7aI.
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
Tandon, Nidhi , Sidana, Surbhi , Lacy, Martha Q. , Kapoor, Prashant , Kourelis, Taxiarchis , Warsame, Rahma , Dingli, David , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Lust, John A., Russell, Stephen J. , Kumar, Shaji , Russell, Stephen J , Sidana, Surbhi , Dingli, David , Rajkumar, S. Vincent , Gertz, Morie A. , Buadi, Francis K. , Gonsalves, Wilson I. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S.

Mayo Clinic

Blood Advances | March 1, 2019 | Volume: 3 | Issue: 5 | Pages: 744-750

10.1182/bloodadvances.2018022806 | PMID 30824418 Get It

Abstract We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response. Early responders after 2 cycles of treatment had higher rates of light chain disease, anemia, renal failure, International Staging System (ISS) stage III disease, and high-risk cytogenetics, especially t(4;14), and were more likely to have received triplet therapy and undergo transplant. Median progression-free survival (PFS) and overall survival (OS) were not different among patients with ≥VGPR and <VGPR after 2 cycles (PFS, 28 vs 30 months, P = .6; OS, 78 vs 96 months, P = .1) and 4 cycles (PFS, 31 vs 29 months; OS, 89 vs 91 months, P = .9), although both were improved, with ≥VGPR as best response (PFS, 33 vs 22 months, P < .001; OS, 102 vs 77 months, P = .003). On multivariate analysis stratified by transplant status, achievement of ≥VGPR after 2 cycles was not associated with improved PFS (hazard ratio [95% confidence interval]; transplant cohort, 1.1 [0.7-1.6]; nontransplant cohort, 1.2 [0.8-1.7]) or OS (transplant cohort, 1.6 [0.9-2.9]; nontransplant cohort, 1.5 [1.0-2.4]). Covariates in the model included high-risk cytogenetics, ISS stage III, triplet therapy, creatinine ≥2 mg/dL, light chain disease, and age. Although patients with high-risk disease are more likely to achieve early response, a rapid achievement of a deep response by itself does not affect long-term outcomes.
Care Transitions Program for High‐Risk Frail Older Adults is Most Beneficial for Patients with Cognitive Impairment
Naessens, James M. , Hanson, Gregory J. , Hickson, LaTonya J. , Chen, Christina Y.Y., Rahman, Parvez, Shah, Nilay D. , Borkenhagen, Lynn S., Chandra, Anupam , Havyer, Rachel D. , Leppin, Aaron L. , Thorsteinsdottir, Bjorg , Peterson, Stephanie M, Chen, Christina Yy, Rahman, Parvez A, Borkenhagen, Lynn, Havyer, Rachel, Leppin, Aaron, Takahashi, Paul Y. , Hickson, LaTonya J , Peterson, Stephanie M, McCoy, Rozalina G. , Hanson, Gregory J

Mayo Clinic

Journal of Hospital Medicine | March 1, 2019 | Volume: 14 | Issue: 6 | Pages: 329-335

10.12788/jhm.3112 | PMID 30794142 Get It

BACKGROUNDAlthough posthospitalization care transitions programs (CTP) are highly diverse, their overall program thoroughness is most predictive of their success.OBJECTIVETo identify components of a successful homebased CTP and patient characteristics that are most predictive of reduced 30‐day readmissions.DESIGNRetrospective cohort.PATIENTSA total of 315 community‐dwelling, hospitalized, older adults (≥60 years) at high risk for readmission (Elder Risk Assessment score ≥16), discharged home over the period of January 1, 2011 to June 30, 2013.SETTINGMidwest primary care practice in an integrated health system.INTERVENTIONEnrollment in a CTP during acute hospitalization.MEASUREMENTSThe primary outcome was all‐cause readmission within 30 days of the first CTP evaluation. Logistic regression was used to examine independent variables, including patient demographics, comorbidities, number of medications, completion, and timing of program fidelity measures, and prior utilization of healthcare.RESULTSThe overall 30‐day readmission rate was 17.1%. The intensity of follow‐up varied among patients, with 17.1% and 50.8% of the patients requiring one and ≥3 home visits, respectively, within 30 days. More than half (54.6%) required visits beyond 30 days. Compared with patients who were not readmitted, readmitted patients were less likely to exhibit cognitive impairment (29.6% vs 46.0%; P = .03) and were more likely to have high medication use (59.3% vs 44.4%; P = .047), more emergency department (ED; 0.8 vs 0.4; P = .03) and primary care visits (4.0 vs 3.0; P = .018), and longer cumulative time in the hospital (4.6 vs 2.5 days; P = .03) within 180 days of the index hospitalization. Multivariable analysis indicated that only cognitive impairment and previous ED visits were important predictors of readmission.CONCLUSIONSNo single CTP component reliably predicted reduced readmission risk. Patients with cognitive impairment and polypharmacy derived the most benefit from the program.
Faculty Opinions recommendation of Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3
Borad, Mitesh J.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 1, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717697919.793152987 Get It

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus stand
Borad, Mitesh J.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 1, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717697918.793152986 Get It

Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma
Rao, Dipti, Berkel, Anouk van , Piscaer, Ianthe, Gruber, Lucinda , Deutschbein, Timo , Beuschlein, Felix , Spyroglou, Ariadni , Prejbisz, Aleksander , Hanuš, K. , Eisenhofer, Graeme , Manelli, Massimo, Lenders, Jacques W.M. , Timmers, Henri , van Berkel, Anouk , Beuschlein, Felix , Rao, Dipti, Young, William F. , Faßnacht, Martin , Canu, Letizia , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 1, 2019 | Volume: 104 | Issue: 9 | Pages: 3812-3820

10.1210/jc.2018-02355 | PMID 30822354 Get It

Abstract Context Cross-sectional imaging with CT or MRI is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial. Objective To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL. Design International multicenter retrospective study. Intervention None. Patients Two hundred thirty-six unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal, and 26 metastatic PPGL. Main Outcome Measures Patients underwent both anatomical imaging (CT and/or MRI) and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses. Results The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively (P = 0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual treatment in four cases (1.2%: two metastatic instead of nonmetastatic, one multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1%: four metastatic instead of nonmetastatic, two multifocal instead of unifocal and one bilateral instead of unilateral adrenal). Conclusions For the initial localization of PPGL, the addition of 123I-MIBG scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.
Automated Parenchymal Pattern Analysis of Treatment Responses in Pulmonary Alveolar Proteinosis
McCarthy, Cormac , Bartholmai, Brian J. , Woods, Jason C. , McCormack, Francis X. , McCormack, Francis X , Bartholmai, Brian J , Trapnell, Bruce C.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 1, 2019 | Volume: 199 | Issue: 9 | Pages: 1151-1152

10.1164/rccm.201810-1918im | PMID 30822107 Get It